文献速递眼底病与葡萄膜炎

非感染性葡萄膜炎与COVID-19结局的关联:美国索赔数据分析

The Association between Noninfectious Uveitis and Coronavirus Disease 2019 Outcomes: An Analysis of United States Claims-Based Data.
PubMed 文献 · Ophthalmology · 2021-10-11

未调整分析中NIU患者COVID-19感染、住院和死亡风险均更高,但调整人口学、合并症及免疫抑制剂使用后,NIU本身与这些结局无显著关联;全身糖皮质激素使用与感染、住院和死亡风险升高显著相关。

要点

  • 调整混杂因素后,NIU与COVID-19感染、住院或死亡风险无显著独立关联。
  • 全身糖皮质激素使用与COVID-19感染、住院和院内死亡风险升高显著相关。
  • NIU患者未调整时结局更差,主要归因于其人口学特征、合并症和用药。

核心结论

  • NIU患者未调整时COVID-19感染、住院和死亡风险更高,但调整后NIU本身并非独立危险因素。
  • 全身糖皮质激素使用与COVID-19感染、住院和院内死亡风险升高显著相关。

研究设计与样本

  • 纳入研究开始前3年连续参加医疗和药品保险的参保者,NIU组为3年内诊断NIU者,排除感染性葡萄膜炎或风险期内新诊断NIU者。
  • 采用Cox比例风险模型计算未调整和调整风险比(HR),调整模型涵盖人口学、健康状况和免疫抑制剂使用。

主要发现

  • 共纳入5 806 227例患者,其中29 869例(0.5%)诊断NIU。
  • 未调整分析:NIU组COVID-19感染率5.7% vs 4.5%(P < 0.001),住院率1.2% vs 0.6%(P < 0.001),死亡率0.3% vs 0.1%(P < 0.001)。
  • 调整模型:NIU与COVID-19感染(HR 1.05,95%CI 1.00-1.10,P = 0.04)、住院(HR 0.98,95%CI 0.88-1.09,P = 0.67)、死亡(HR 0.90,95%CI 0.72-1.13,P = 0.37)无显著关联。
  • 全身糖皮质激素使用与COVID-19感染、住院和死亡风险升高显著相关。

关键数值与推荐

  • COVID-19感染、住院和院内死亡通过ICD-10编码识别。
  • 调整模型纳入人口学、健康状况和免疫抑制剂使用等协变量。

临床怎么用

  • 评估NIU患者COVID-19风险时应考虑其合并症和用药,而非仅归因于葡萄膜炎本身。
  • 对使用全身糖皮质激素的患者需警惕COVID-19感染及重症风险。

局限性

  • 基于索赔数据的回顾性研究,可能存在编码偏倚和混杂残余。
  • 研究仅覆盖2020年,结论外推需谨慎。
  • 需进一步研究糖皮质激素暴露对COVID-19结局的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To identify if noninfectious uveitis (NIU) is associated with a greater risk of Coronavirus Disease 2019 (COVID-19) infection, hospitalization, and death. DESIGN: A retrospective cohort study from January 20, 2020 to December 31, 2020, using a national claims-based database. PARTICIPANTS: Enrollees who had continuous enrollment with both medical and pharmacy coverage for 3 years before January 20, 2020. Patients with an NIU diagnosis within 3 years of the start of the study were included in the NIU cohort. Those with infectious uveitis codes or new NIU diagnoses during the risk period were excluded. METHODS: Cox proportional hazard models were used to identify unadjusted hazard ratios (HRs) and adjusted HRs for all covariates for each outcome measure. Adjusted models accounted for patient demographics, health status, and immunosuppressive medication use during the risk period. MAIN OUTCOME MEASURES: Rates of COVID-19 infection, COVID-19-related hospitalization, and COVID-19-related in-hospital death identified with International Classification of Disease 10th revision codes. RESULTS: This study included 5 806 227 patients, of whom 29 869 (0.5%) had a diagnosis of NIU. On unadjusted analysis, patients with NIU had a higher rate of COVID-19 infection (5.7% vs. 4.5%, P < 0.001), COVID-19-related hospitalization (1.2% vs. 0.6%, P < 0.001), and COVID-19-related death (0.3% vs. 0.1%, P < 0.001). However, in adjusted models, NIU was not associated with a greater risk of COVID-19 infection (HR, 1.05; 95% confidence interval [CI], 1.00-1.10; P = 0.04), hospitalization (HR, 0.98; 95% CI, 0.88-1.09; P = 0.67), or death (HR, 0.90, 95% CI, 0.72-1.13, P = 0.37). Use of systemic corticosteroids was significantly associated with a higher risk of COVID-19 infection, hospitalization, and death. CONCLUSIONS: Patients with NIU were significantly more likely to be infected with COVID-19 and experience severe disease outcomes. However, this association was due to the demographics, comorbidities, and medications of patients with NIU, rather than NIU alone. Patients using systemic corticosteroids were significantly more likely to be infected with COVID-19 and were at greater risk of hospitalization and in-hospital death. Additional investigation is necessary to identify the impact of corticosteroid exposure on COVID-19-related outcomes.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Miller DC, Sun Y, Chen EM, et al. The Association between Noninfectious Uveitis and Coronavirus Disease 2019 Outcomes: An Analysis of United States Claims-Based Data. Ophthalmology. 2021. PMID: 34648828. doi:10.1016/j.ophtha.2021.10.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。